EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Sir Chris Hoy hailed the fundraising as a “huge step forward” in the fight to make change. "The huge sum Paddy Power are ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Colorectal Cancer.

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Prostate cancer is one of the most common cancers in men worldwide, primarily affecting older men. The prostate is a small, walnut-shaped gland located just below the bladder and in front of the ...

According to GlobalData, Phase II drugs for Androgen-Sensitive Prostate Cancer does not have ... a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung ...

The 5-year survival rates for prostate cancer at various stages are as follows: Localized and regional: around 99% for both Black and white men Advanced disease: around 30% in Black and white men ...

Gemini Advanced subscribers are getting access to a new “Deep Research” capability. It is the “first feature in Gemini” to bring Google’s vision of agents that can perform complex ...

This study aims to report the oncological, surgical and functional outcomes in 15 patients with locally advanced penile cancer who underwent total penile ... were assessed by the International ...

New research by a team of Indiana University School of Medicine scientists and their collaborators has uncovered a novel vulnerability in prostate cancer animal models that starves prostate tumors ...